4.7 Article

MiR-142-3p enhances chemosensitivity of breast cancer cells and inhibits autophagy by targeting HMGB1

Journal

ACTA PHARMACEUTICA SINICA B
Volume 10, Issue 6, Pages 1036-1046

Publisher

INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES
DOI: 10.1016/j.apsb.2019.11.009

Keywords

Breast cancer; MCF-7 cell line; HMGB1; MiR-142-3p; Drug resistance; Chemosensitivity

Funding

  1. National Natural Science Foundation of China [81700382]
  2. Science and Technology Programs of Guangdong Province [2014A050503047, 2015B020225006]

Ask authors/readers for more resources

MiR-142-3p has been reported to act as a tumor suppressor in breast cancer. However, the regulatory effect of miR-142-3p on drug resistance of breast cancer cells and its underlying mechanism remain unknown. Here, we found that miR-142-3p was significantly downregulated in the doxorubicin (DOX)-resistant MCF-7 cell line (MCF-7/DOX). MiR-142-3p overexpression increased DOX sensitivity and enhanced DOX-induced apoptosis in breast cancer cells. High-mobility group box 1 (HNIGB1) is a direct functional target of miR-142-3p in breast cancer cells and miR-142-3p negatively regulated HNIGB1 expression. Moreover, overexpression of HMGB1 dramatically reversed the promotion of apoptosis and inhibition of autophagy mediated by miR-142-3p up-regulation. In conclusion, miR-142-3p overexpression may inhibit autophagy and promote the drug sensitivity of breast cancer cells to DOX by targeting HNIGB1. The miR-142-3p/HNIGB1 axis might be a novel target to regulate the drug resistance of breast cancer patients. (C) 2020 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available